Intelligent Bio Solutions INC 8-K filings

Intelligent Bio Solutions Inc. submitted its Additional Information response to the FDA, strengthening its 510(k) clearance package for U.S. market entry.

Intelligent Bio Solutions Inc. announced a warrant inducement offer expected to generate approximately $3.8 million in gross proceeds to fund its FDA 510k filing for the Fingerprint Drug Screening System.

Intelligent Bio Solutions Inc. announced the successful collection of new data reinforcing the security and performance of its Intelligent Fingerprinting Drug Screening System, strengthening its FDA 510(k) submission.

Intelligent Bio Solutions Inc. announced a new global distribution agreement with SMARTOX to bring its SmarTest Patch drug detection product to international markets outside the U.S. and Canada, reinforcing its position in non-invasive drug testing.

Intelligent Bio Solutions Inc. announced the strategic addition of the SmarTest Patch, a wearable device enabling continuous drug detection through sweat over 7 to 10 days, significantly expanding its non-invasive testing solutions.

Intelligent Bio Solutions Inc. has amended the employment agreements for its President and CEO, Harry Simeondis, and CFO, Spiro Sakiris, increasing their base salaries and enhancing severance benefits, particularly in the event of a Change in Control.

Intelligent Bio Solutions Inc. announces significant growth in global operations, exceeding 450 active accounts across 24 countries due to increased adoption of its fingerprint drug testing system.

Intelligent Bio Solutions Inc. announced a 20% sequential quarterly revenue increase and a 91% year-over-year gross profit increase for fiscal Q3 2025, fueled by growing cartridge sales and customer acquisition.

Intelligent Bio Solutions has been granted a U.S. patent for its Intelligent Fingerprinting Drug Screening Cartridge, strengthening its intellectual property protection ahead of its planned 2025 U.S. market entry.

Intelligent Bio Solutions Inc. provides an update on its FDA clearance process for its Intelligent Fingerprint Drug Screening System, reaffirming its planned U.S. launch in 2025.

Intelligent Bio Solutions expects to receive its sixth U.S. patent, strengthening protection for its fingerprint-based drug testing technology.

Intelligent Bio Solutions Inc. announces the date and record date for its 2024 annual meeting of stockholders, along with deadlines for shareholder proposals and director nominations.

Intelligent Bio Solutions Inc. has filed a prospectus supplement to offer and sell up to $1,376,530.39 of its common stock under an existing At-The-Market Offering Agreement.

Intelligent Bio Solutions Inc. closed a public offering of common stock, raising $3 million after the underwriter fully exercised their option to purchase additional shares.

Intelligent Bio Solutions Inc. announced its fiscal Q2 2025 financial results, showcasing a 32.6% increase in gross profit and progress towards entering the U.S. market.

Intelligent Bio Solutions recapped its 2024 growth, highlighting a 148% year-over-year revenue increase and its plans for U.S. market expansion in 2025 following FDA 510(k) submission.

Intelligent Bio Solutions Inc. (INBS) partners with Avon Freight Group to implement its fingerprint drug testing solution across three UK sites, signaling growth and a focus on U.S. expansion.

Intelligent Bio Solutions expects a 32.6% increase in gross profit and improved profitability driven by higher-margin cartridge sales.

Intelligent Bio Solutions announces a major upgrade to its drug screening system, adding multilingual support to reach over 4 billion users globally.

Quantum Traffic Management, a UK-based traffic management provider, has adopted Intelligent Bio Solutions' fingerprint drug testing solution to improve workplace testing efficiency and safety across its 10 nationwide sites.

Intelligent Bio Solutions partners with IVY Diagnostics to expand its drug screening technology into the European and Middle Eastern markets.

Intelligent Bio Solutions Inc. reports a total of 4,807,068 outstanding shares of common stock as of January 2, 2025, following recent equity sales and stock issuances.

Intelligent Bio Solutions has submitted its 510(k) premarket notification to the FDA for its fingerprint-based drug screening system, marking a significant step towards US market entry.

Intelligent Bio Solutions Inc. released a presentation on December 3, 2024, detailing the company's business and operations.

Intelligent Bio Solutions has successfully completed a method comparison study for its fingerprint drug screening system, demonstrating 94.1% accuracy and paving the way for an FDA 510(k) submission.

Intelligent Bio Solutions Inc. released a video detailing initial results from its Pharmacokinetic study and disclosed raising $250,802 through share sales.

Intelligent Bio Solutions reports successful initial results from its Pharmacokinetic study, demonstrating that fingerprint sweat is a reliable sample for drug detection, a key step towards FDA 510(k) submission.

Intelligent Bio Solutions announced a 10% year-on-year revenue increase and progress towards FDA 510(k) submission for its fingerprint drug screening system.

Intelligent Bio Solutions announced a 10% year-on-year and 20% quarter-on-quarter increase in preliminary unaudited revenue for the first fiscal quarter of 2025, driven by higher-margin cartridge sales.

Intelligent Bio Solutions granted special one-time stock awards to its CEO and CFO as part of its 2024 compensation review.